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Methods. We studied two patients with type IV glycogen storage disease 37 and 91 months after liver transplantation and a third patient with lysosomal glucocerebrosidase deficiency (type 1 Gaucher's disease), in whom tissue glucocerebroside deposition had decreased 26 months after liver replacement, to determine whether the migration of cells from the allograft (microchimerism) could explain the improved metabolism of enzyme-deficient tissues in the recipient. Samples of blood and biopsy specimens of the skin, lymph nodes, heart, bone marrow, or intestine were examined immunocytochemically with the use of donor-specific monoclonal anti-HLA antibodies and the polymerase chain reaction, with preliminary amplification specific to donor alleles of the gene for the beta I N patients with type IV glycogen storage disease, deficiency of the branching enzyme alpha-l,4-glucan:alpha-l,4-g1ucan 6-glucosyltransferase is responsible for the accumulation in the liver and elsewhere of an insoluble and irritating amylopectin-like polysaccharide.! We recently described the absorption of this amylopectin from the extrahepatic tissues after liver transplantation,2leading Howell to predict that an explanation of the benefit would "clearly teach us a great deal about transplantation.,, 3 That prediction has been shown to be accurate by our observation in this study that patients with type IV glycogen storage disease in whom liver transplantation was successful chain of HLA-DR molecules, followed by hybridization with allele-specific oligonucleotide probes.
Results. Histopathological examination revealed that the cardiac deposits of amylopectin in the patients with glycogen storage disease and the lymph-node deposits of glucocerebroside in the patient with Gaucher's disease were dramatically reduced after transplantation. Immunocytochemical analysis showed cells containing the HLA phenotypes of the donor in the heart and skin of the patients with glycogen storage disease and in the lymph nodes, but not the skin, of the patient with Gaucher's disease. Polymerase-chain-reaction analysis demonstrated donor HLA-DR DNA in the heart of both patients with glycogen storage disease, in the skin of one of them, and in the skin, intestine, blood, and bone marrow of the patient with Gaucher's disease.
Conclusions. Systemic microchimerism occurs after liver allotransplantation and can ameliorate pan cellular enzyme deficiencies. (N Engl J Med 1993;328:745-9.) became chimeras: the cells of the host organs became mixed with cells of the donor genome that had migrated from the allograft into the tissues of the recipient and apparently served as enzyme carriers. We also found evidence of similar chimerism and consequent metabolic benefits after liver transplantation in a patient who had type I Gaucher's disease, a disorder caused by a deficiency of the lysosomal enzyme betagl ucocere brosidase. 4 
CASE REPORTS

Patients 1 and 2 (Type IV Glycogen Storage Disease)
In April 1992, biopsy specimens of liver, endomyocardium, and skin were obtained from Patients I and 2, two brothers with type IV glycogen storage disease who had undergone liver replacement for hepatic failure 91 and 37 months earlier. z The patients were 31 and 20 months old at the time of transplantation and were subsequently treated with cyclosporine and prednisone. Their physical and intellectual development has been steady since the operation. Because of hepa tic failure and recurrent bleeding from esophageal varic es, the patient underwent orth oto pic liv er transplantation in April 1990. Thereafter, he was treated with FK 506 and prednisone. His liver function has been norm al since then , and hi s s evere preexisting muscle weakness has s teadily improved. In july 1990, three months after liver tra nspla ntation , enzyme treatment was resumed. In june 1992, 26 months after li ve r replacement, biopsy s peci mens were obtained from th e a llograft, skin, lymph nod e, jejunum (by endos co py)' and iliac-crest bone marrow.
METHODS
The transplantation and biopsy procedures were considered essential for optima l care of all three patients and were performed with their parents' consent. Tissues were fix ed in 10 perce nt formalin for conventional st'-lining and frozen in Optimu m Cold Temperature medium (OCT , Tissue-Tek, Ames Divis ion, Miles La boratories , Elkhart, Ind .) for immunocy tochemi ca l eva luat ion or in liquid nitroge n for D NA typing. Gaucher's cells and amylopectin inclusions were examined by lig ht microscopy a fter staining: with periodic acid -Schiff sta in ( PAS) with and without di as tase digestion ( PAS-D ).
Immunocytochemical Evaluation
The HLA typ es of the three donors were d etermined at the time of organ procureme nt (September 1984 in the donor for Patient I , March 1989 in the donor for Patient 2, and April 1990 in the donor for Pa tie nt 3). The HLA types of the recipients were determined just befo re tra nspl an tat ion. After invest iga tors established which class I and class 11 antigens were present in the donor but not in the recipient, monoclonal antibodies we re c hose n from a library (w hose sources were Ameri can Tiss ue and Cell Culture, Genetic Synterus, Seattle, and One Lambda, Canoga Park , Calif.) and used for phen otyping of the biops y specimens by ind irect immun oflu oresce nce and immunoperox id ase (avidin -biotin complex ) methods . The liver removed at the time of transplantation was used as a nega tive control for donor-s pecific antibodies; as an additio nal negative-control measure, staining was ca rried out with irreleva nt anti -HLA antibodies and omission of the primary antibody. Li ve rs with known HLA phenoty pes sta ined with mat ching a n ti -HLA monoclonal antibodies were used as pos itive contro ls.
Polymerase Chain Reaction
M olec ular typing o f the beta chain of HLA-DR molecules was perform ed with use of the po lymerase chain rea ct ion, according to the protocol of the II th International Histocompatib ility Workshop, ' in whi ch preliminary amplificati on of the HLA-DR bctachain gene is performed before allele-specific am plification.
RESULTS
Histologic Studies
Patients with Glycogen Storage Disease
In the patients with glycogen storage disease neither of the liver allografts had evidence of rejection or amylopectin deposition. At the time of our pr vio us report on these patients,2 the area of heart tissue replaced by amylo pec tin in the younger brother (Patient 2) had decreased from 13 to 6 percent 14 months after transplan tation. A furt her reduction to less than I percent occurred during the ensuing 22 months (Fig. I ) . The heart of the older brother (Patient I) was almost free of amylopectin when the first biopsy was performed , more than 5 years after transplantation 2 ; it appeared the sa me 91 months after transplantation.
Patient with Gaucher's Disease
A hilar lymph node removed with the native liver from the patient with Gaucher's disease in April 1990 contained numerous glucocerebroside-filled cells that profoundly distorted the nodal architecture. An inguinal lymph node removed 26 months later contained only a few of these cells, located predominantly in the medullary sinuses (Fig. 2) . A biopsy of the allograft performed 26 months after transplantation showed that the architecture of the g raft was intact , with no evidence of rejection and only a few Gaucher's cells scattered in the sinusoids . Specimens of the skin and small intestine were normal, and the bone marrow cont ained only very few Gaucher's cells.
Immunocytochemical Studies
The end othelium and bil e du cts of all three patients retained the phenotypes of the donors , whereas most of the KupfTer cells of the liver were replaced by those of the recipient, as previously described. 6 . a Cells of the donor phenotype were found in the hearts of both patients with glycogen storage disease (Table I) . These cells constituted a minority of the interstitial cardiac cells and were seen at a density of 8 to 10 cells per square millimeter in ul trathin sections (2 J-Lm) (Fig. 3) . The vascular endothelial cells of the heart were exclusively of the phenotype of the recipient. The skin of both patients contained donor cells interspersed among the cells of the basal layer of epidermis and in the periadventitial tissue of dermal blood vessels. All epidermal and vascular endothelial cells had the recipi ent' s phenotype. Cells with the donor's phenotype could be found in the lymph nodes but not the skin of the patient with Gaucher's disease (Table I) .
Polymerase Chain Reaction
Chimerism was observed in the hearts of both patients with glycogen storage disease and in the skin of one of them on polymerase-chain-reaction analysis ( Table 2 ). The HLA type of the patient with Gaucher's disease was DR2, 7, and that of the donor was DRI,II (Table I) . When HLA-DRI-specific primers and probes were used (Fig. 4) , the donor's DNA was found in the blood, bone marrow, skin, and small bowel of the recipient (Table 2) . DISCUSSION The resorption of amylopectin from the heart previously reported after liver transplantation in patients with glycogen storage disease 2 was confirmed by endomyocardial biopsies after additional months of follow-up. Donor cells could be detected in the biopsy specimens and other tissues of the recipients by immunocytochemical and molecular techniques 91 and 37 months, respectively, after liver replacement. Similar donor cells were also found in the skin, lymph nodes, small bowel, bone marrow, and blood of a patient with Gaucher's disease.
We have proposed elsewhere 6 ,9,IO that the successful engraftment of all whole-organ transplants connotes (and requires) an exchange between the organ and the recipient of cells of lymphocyte-macrophage lineage. Although the same process occurs with all organs, the high density and quality of the migratory cells leaving the liver or coming to it from the recipient are thought to be the basis for the "immunologic privilege" of a hepatic graft,6,9,IO including its socalled tolerogenicity in other organs from the same donor .11
The bone marrow-derived dendritic (antigen presenting) cells delineated by Steinman and Cohn l 2 that are normally associated with the induction of T-cell im muni ty rather than the induction of tolerance l3 ,14 are thought to be the most prominent of the migratory cells moving from the liver to distant host tissues, with r placemen t by similar cells of the recipient that home to the graft. The distribution of the donor cells is similar to their distribution after bone marrow transplantation. 6 ,15,16 T he consequent chimerism explains why the liver allograft can cause graft-versus-host disease. I 7-20 T he occu rre nce of cell migration after liver tra nsplan tation explains why pati en ts with lysosomal storage disorders -Wolma n's d isease,2 1 Niemann-Pi ck disease,22 Gaucher's d isease,23 and the sea-blue histiocyte synd rom e (unpublished data ) -receive more benefi t from liver repla cement than simply improved hepatic fun ction 24 We had assumed that the lysosomal sto rage disorder of our patient with Gaucher's disease wo uld progress after transplantation, prompting us to resume enzyme therapy ; we now suspect that su ch trea tment was unnecessary. For the absorption of the in tracellular and extracellular amylopectin deposits of type IV glycogen storage disease, as well as the intracellular glucocerebroside deposits of G aucher's d isease, it is necessary for the enzyme prod uced by the donor cells to gain access to the substrate. Evidence from in vitro coculture experiments suggests that once the donor cells have moved to the appropriate location, an enzyme can be transported from normal to abnormal cells. 25 The number of allogeneic cells required to produce a metabolic effect appears from our results to be surprisingly low. The presumed transmission of enzymes from a small to a larger cell population raises intriguing questions about the potential cell-to-cell transfer of other molecules , including those involved in immunologic processes.
With the fuller understanding of what is actually accomplished by liver transpl anta tion, past conclusions about the mechanisms of inborn errors of metabolism that were deduced from studies of livertransplant recipients will require reexamination . For Gaucher's Disease. Genomic DNA was extracted from the recipient's tissues and amplilied with HLA-DR beta-chain "generic" oligonucleotide primers to determine the subgroup of the donor's alleles. "Specific' primers were then used to amplify the alleles selectively. The all eles were identified by hybridizing the amplified DNA to radiolabeled allele-specific probes. After HLA-DR1-specific amplification of DNA from the liver, blood, bone marrow, skin, and small bowel, the DNA was separated by electrophoresis on an agarose gel and then analyzed by Southern blotting. The denatured DNA present on the nylon membrane was hybridized to a labeled HLA-DR 1 (donor)-specilic oligonucleotide probe. For liver DNA, the quantity analyzed was reduced to 1 percent of the other samples. Although lower in intensity, the signal from donor DNA in the small bowel was clearly positive in the original film, although this can be seen only faintly . The negative control was a reaction run without DNA (last lane).
exampl e, the decline in serum cholesterol concentrations after liver transplantation in patients with familial hypercholesterolemia 26 that was ascribed to the low-density lipoprotein receptors of the allograft hepatocytes 27 may reflect in part the presence of these receptors on widely disseminated donor cells that are not hepatocytes. Migratory Kupffer cells alone account for 10 to 15 percent of all cells in the liver and one fifth of the lotal hepatic lysosomal volume. 28 If, as we have proposed ,6,9,IO microchimerism differing only in degree is an integral feature of the successful engraftment of any organ, all such transplantation procedures could result in a gain in metabolic function. This could explain the report by Desnick et al 29 that native kidneys that had failed as a result of the accumulation of glycosphingolipid in a patient with Fabry's disease recovered their function after successful renal transplantation.
